AUGX logo

Augmedix, Inc. (AUGX) Aktienanalyse

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Augmedix, Inc. (AUGX) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 58/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 15. März 2026
58/100 KI-Bewertung

Augmedix, Inc. (AUGX) Gesundheitswesen & Pipeline-Uebersicht

CEOEmmanuel Krakaris
Mitarbeiter1430
HauptsitzSan Francisco, US
IPO-Jahr2021

Augmedix, Inc. offers remote medical documentation solutions and live clinical support, enhancing clinician efficiency through its Augmedix Live and Notes platforms. Serving health systems and specialty groups, the company leverages mobile devices to streamline pre-, during-, and post-visit documentation, positioning itself within the growing healthcare information services market.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 15. März 2026

Investmentthese

Augmedix, Inc. presents an intriguing investment opportunity within the healthcare information services sector. The company's focus on leveraging technology to streamline medical documentation addresses a significant pain point for healthcare providers. Key value drivers include the increasing adoption of telehealth and remote patient monitoring, which drives demand for efficient documentation solutions. Growth catalysts include expanding partnerships with health systems and specialty groups, as well as the potential for international expansion. However, the company's negative profit margin of -42.7% and a P/E ratio of -5.38 highlight the risks associated with profitability and valuation. Investors should closely monitor the company's ability to scale its operations, improve its financial performance, and navigate the competitive landscape.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $0.12 billion indicates the company's current valuation in the market.
  • Gross margin of 48.0% reflects the company's ability to generate revenue after accounting for the cost of goods sold.
  • Negative profit margin of -42.7% suggests the company is currently operating at a loss.
  • Beta of -0.19 indicates the stock is less volatile than the overall market.
  • The company employs 1430 individuals, reflecting its operational scale and service delivery capacity.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Proprietary technology platform for remote medical documentation
  • Established relationships with health systems and specialty groups
  • Expertise in healthcare workflows and regulatory compliance
  • Scalable business model with recurring revenue streams

Schwaechen

  • Negative profit margin and ongoing losses
  • Reliance on a limited number of large customers
  • Competition from established players and emerging technology companies
  • Potential for cybersecurity breaches and data privacy violations

Katalysatoren

  • Upcoming: Potential new partnerships with large hospital networks by Q4 2026, expanding market reach.
  • Ongoing: Increasing adoption of telehealth services driving demand for remote documentation solutions.
  • Ongoing: Focus on AI-driven automation to improve efficiency and reduce costs.

Risiken

  • Potential: Changes in healthcare regulations impacting reimbursement models.
  • Potential: Increased competition from other healthcare technology providers.
  • Ongoing: Data security and privacy concerns related to handling sensitive patient information.

Wachstumschancen

  • Expansion into new therapeutic areas represents a significant growth opportunity for Augmedix. By tailoring its solutions to specific medical specialties, such as cardiology, oncology, or orthopedics, the company can address the unique documentation needs of these areas. This targeted approach can drive adoption and increase revenue within these specialized markets. The market size for each therapeutic area varies, but the combined potential represents a substantial growth opportunity over the next 3-5 years.
  • Geographic expansion beyond the United States offers another avenue for growth. The demand for efficient medical documentation solutions is global, and Augmedix can leverage its technology platform to serve healthcare providers in other countries. Initial target markets could include Canada, the United Kingdom, and Australia, where healthcare systems are similar to the United States. This expansion could occur within the next 2-4 years, contingent on regulatory approvals and market entry strategies.
  • Strategic partnerships with EHR vendors can accelerate Augmedix's market penetration. By integrating its solutions with leading EHR platforms, the company can seamlessly embed its services into existing healthcare workflows. This integration can streamline the user experience and drive adoption among healthcare providers who are already using these EHR systems. These partnerships could be established within the next 1-2 years, providing immediate access to a large customer base.
  • Development of AI-powered documentation tools can enhance the efficiency and accuracy of Augmedix's solutions. By leveraging artificial intelligence and machine learning, the company can automate certain aspects of the documentation process, such as data extraction and summarization. This can further reduce the administrative burden on clinicians and improve the quality of medical notes. The development and deployment of these AI tools could occur within the next 2-3 years, providing a significant competitive advantage.
  • Offering specialized solutions for telehealth platforms represents a growing opportunity. As telehealth adoption continues to increase, the need for efficient documentation solutions tailored to virtual care settings is becoming more critical. Augmedix can develop specialized features and workflows that address the unique challenges of telehealth, such as remote patient monitoring and virtual consultations. This offering could be launched within the next 1-2 years, capitalizing on the rapid growth of the telehealth market.

Chancen

  • Expansion into new therapeutic areas and geographic markets
  • Strategic partnerships with EHR vendors and telehealth platforms
  • Development of AI-powered documentation tools
  • Increasing adoption of telehealth and remote patient monitoring

Risiken

  • Changes in healthcare regulations and reimbursement policies
  • Economic downturn and reduced healthcare spending
  • Technological obsolescence and disruption from new entrants
  • Data security breaches and privacy concerns

Wettbewerbsvorteile

  • Proprietary technology platform for remote medical documentation.
  • Established relationships with health systems and specialty groups.
  • Expertise in healthcare workflows and regulatory compliance.
  • Data network effects: As more clinicians use the platform, the AI models improve, enhancing the service.

Ueber AUGX

Founded in 2013 and headquartered in San Francisco, California, Augmedix, Inc. is dedicated to transforming healthcare delivery through its remote medical documentation and live clinical support services. The company's core offering revolves around its Augmedix platform, which includes Augmedix Live and Augmedix Notes solutions. These solutions address critical documentation needs at every stage of the patient visit, from pre-visit preparation, including pre-charting and digitization of patient history, to during-visit support with medical notes, care gap reminders, and after-visit summaries encompassing coding, orders, and referrals. Augmedix enables clinicians to access these applications via mobile devices, including smartphones and Google Glass, promoting flexibility and accessibility. Augmedix partners with health systems and specialty groups across the United States, aiming to alleviate administrative burdens on healthcare professionals, improve documentation accuracy, and ultimately enhance the patient care experience. The company's focus on technology-driven solutions positions it within the rapidly evolving healthcare information services sector, where efficiency and data management are increasingly vital.

Was das Unternehmen tut

  • Provides remote medical documentation solutions to healthcare providers.
  • Offers live clinical support services to physicians and other clinicians.
  • Streamlines pre-visit documentation, including pre-charting and patient history digitization.
  • Facilitates during-visit documentation, such as medical notes and care gap reminders.
  • Handles post-visit documentation, including coding, orders, and referrals.
  • Enables clinicians to access applications through mobile devices like smartphones and Google Glass.

Geschaeftsmodell

  • Augmedix generates revenue by providing subscription-based access to its platform.
  • The company charges fees for its remote medical documentation and live clinical support services.
  • Pricing models may vary based on the number of clinicians served and the volume of documentation processed.

Branchenkontext

Augmedix operates within the healthcare information services industry, a sector experiencing rapid growth driven by the increasing adoption of electronic health records (EHRs), telehealth, and value-based care models. The market is characterized by intense competition among established players and emerging technology companies. Augmedix differentiates itself through its focus on remote medical documentation and live clinical support, catering to the growing demand for efficient and streamlined healthcare workflows. The industry is projected to continue its growth trajectory, fueled by the need to reduce administrative burdens on healthcare providers and improve patient outcomes.

Wichtige Kunden

  • Health systems seeking to improve clinician efficiency and reduce administrative burdens.
  • Specialty groups looking to streamline documentation workflows and enhance patient care.
  • Individual physicians and clinicians seeking remote support for medical documentation tasks.
KI-Zuversicht: 71% Aktualisiert: 15. März 2026

Finanzdaten

Chart & Info

Augmedix, Inc. (AUGX) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer AUGX.

Kursziele

Wall-Street-Kurszielanalyse fuer AUGX.

MoonshotScore

58/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von AUGX auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: Emmanuel Krakaris

CEO

Emmanuel Krakaris serves as the CEO of Augmedix, Inc., leading the company's strategic direction and operational execution. His background includes extensive experience in healthcare technology and management. Before joining Augmedix, he held leadership positions at various healthcare companies, focusing on innovation and growth. He brings a wealth of knowledge in healthcare information services and a commitment to improving patient care through technology.

Erfolgsbilanz: Since assuming the role of CEO, Emmanuel Krakaris has focused on expanding Augmedix's market reach and enhancing its technology platform. Key achievements include securing partnerships with major health systems and driving innovation in AI-powered documentation tools. Under his leadership, the company has navigated the challenges of the evolving healthcare landscape and positioned itself for future growth.

Augmedix, Inc. Aktie: Wichtige Fragen beantwortet

What are the key factors to evaluate for AUGX?

Augmedix, Inc. (AUGX) currently holds an AI score of 58/100, indicating moderate score. Key strength: Proprietary technology platform for remote medical documentation. Primary risk to monitor: Potential: Changes in healthcare regulations impacting reimbursement models.. This is not financial advice.

How frequently does AUGX data refresh on this page?

AUGX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven AUGX's recent stock price performance?

Recent price movement in Augmedix, Inc. (AUGX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary technology platform for remote medical documentation. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider AUGX overvalued or undervalued right now?

Determining whether Augmedix, Inc. (AUGX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying AUGX?

Before investing in Augmedix, Inc. (AUGX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding AUGX to a portfolio?

Potential reasons to consider Augmedix, Inc. (AUGX) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary technology platform for remote medical documentation. Additionally: Established relationships with health systems and specialty groups. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of AUGX?

Yes, most major brokerages offer fractional shares of Augmedix, Inc. (AUGX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track AUGX's earnings and financial reports?

Augmedix, Inc. (AUGX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for AUGX earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Financial data is based on the most recent available information.
  • AI analysis is pending and may provide further insights.
Datenquellen

Popular Stocks